Use of lopinavir in preparation of medicines for preventing or treating acute lung injury/acute respiratory distress syndrome and pulmonary fibrosis

A technology for acute respiratory distress and acute lung injury, applied in the field of application of lopinavir in the preparation of drugs for the prevention or treatment of acute lung injury/acute respiratory distress syndrome and pulmonary fibrosis, which can solve the pharmacological effects and has not been reported And other issues

Inactive Publication Date: 2014-10-08
BINZHOU MEDICAL COLLEGE
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Clinically, the combination of lopinavir and ritonavir (trade name Kaletra) is used for the treatment of HIV/AIDS infection, and it can also be used in combination with other antiretroviral drugs for

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of lopinavir in preparation of medicines for preventing or treating acute lung injury/acute respiratory distress syndrome and pulmonary fibrosis
  • Use of lopinavir in preparation of medicines for preventing or treating acute lung injury/acute respiratory distress syndrome and pulmonary fibrosis
  • Use of lopinavir in preparation of medicines for preventing or treating acute lung injury/acute respiratory distress syndrome and pulmonary fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0012] Example 1 Preparation of Lopinavir Tablets

[0013] Weigh 120.0g lopinavir and 80.0g carboxymethyl starch sodium, mix well and pass through a 100-mesh sieve, add an appropriate amount of 3% PVP K30 Appropriate amount of water solution to make soft material, granulate with 20-mesh sieve, dry at 60°C for 3 hours, granulate with 18-mesh sieve, add 2.0g of magnesium stearate, mix well and press into tablets, adjust the weight of the tablet to about 200mg.

experiment example 2

[0026] Experimental Example 2 Effect of Lopinavir on Acute Lung Injury / Acute Respiratory Distress Syndrome (ALI / ARDS) Model Rats Induced by Cecal Ligation and Perforation

[0027] 2.1 Drugs and reagents

[0028] Lopinavir (purity 99.5%, purchased from Shanghai Hanxiang Biotechnology Co., Ltd.)

[0029] Limulus reagent kit (Fuzhou Xinbei Biochemical Industry Co., Ltd., Fujian Province, batch number: 080430)

[0030] Anti-Aquaporin5 antibody (abcam company, ab104751)

[0031] RAGE primary antibody was purchased from Sigma.

[0032] Experimental animals: SPF grade Sprague Dawley rats, male, weighing 150g-200g, provided by the Experimental Animal Center of Shandong Luye Pharmaceutical Co., Ltd., the animal qualification certificate number is: SYXK (Lu) 20030020.

[0033] 2.2 Experimental methods and results

[0034] 2.2.1 Preparation of rats with cecal ligation and puncture (CLP)

[0035] On the day of the operation, the rats were fasted in the morning, placed in the supine pos...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a new medical use of lopinavir and specifically relates to a use of the lopinavir in preventing or treating acute lung injury/acute respiratory distress syndrome (ALI/ARDS) and pulmonary fibrosis by inhibiting the apoptosis of type I alveolar epithelial cells, promoting the expression of the receptor for advanced glycation endproducts of the type I alveolar epithelial cells, further inhibiting the occurrence and development of ALI/ARDS and the pulmonary fibrosis and finally preventing or treating ALI/ARDS. In the use, the dosage of the lopinavir ranges from 100mg to 6000mg, preferably from 240mg to 3000mg.

Description

technical field [0001] The present invention relates to that lopinavir suppresses the occurrence and development of acute lung injury / acute respiratory distress syndrome (ALI / ARDS) and pulmonary fibrosis so as to prevent or treat ALI / ARDS and pulmonary fibrosis; Type I alveolar epithelial cell apoptosis, promote the expression of receptor for advanced glycation endproducts (RAGE) in type I alveolar epithelial cells, so as to prevent or treat ALI / ARDS and pulmonary fibrosis. Background technique [0002] Acute lung injury / acute respiratory distress syndrome (ALI / ARDS) is a common critical illness with a high mortality rate, which seriously threatens the life of critically ill patients and affects their quality of life. ALI / ARDS is acute hypoxic respiratory function caused by diffuse pulmonary interstitial and alveolar edema caused by damage to pulmonary capillary endothelial cells and alveolar epithelial cells during non-cardiogenic diseases such as severe infection, shock, t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/513A61P11/00
Inventor 蒋王林纪云霞张亮吕长俊
Owner BINZHOU MEDICAL COLLEGE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap